Spots Global Cancer Trial Database for neurofibromatosis
Every month we try and update this database with for neurofibromatosis cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients | NCT01222728 | Neoplasms Nervous System ... Vestibular Dise... | 18 Years - 50 Years | National Institutes of Health Clinical Center (CC) | ||
| Clinical Trial of Pirfenidone in Adult Patients With Neurofibromatosis 1 | NCT00754780 | Neurofibromatos... | Pirfenidone | 18 Years - 70 Years | Mayo Clinic | |
| Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas | NCT01275586 | Neurofibromatos... NF1 Neurofibromas | Tasigna | 18 Years - | Indiana University | |
| How Neurofibromatosis Type 1 (NF1) Affects Schoolwork and Self-Esteem | NCT01626846 | Neurofibromatos... | 14 Years - 17 Years | John Jay High School | ||
| Individual Patient Compassionate Use of Mirdametinib | NCT05028166 | Neurofibromatos... Histiocytic Neo... Other MAP-K Pat... | Mirdametinib (M... | 2 Years - | SpringWorks Therapeutics, Inc. | |
| DPCP to Treat Cutaneous Neurofibromas Associated With NF1 | NCT05438290 | Cutaneous Neuro... | DPCP | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Natural History Study of Cutaneous Neurofibromas in People With NF1 | NCT05581511 | Neurofibromatos... Neurofibromatos... Neurofibromatos... Cutaneous Neuro... | Evaluation of t... | 1 Year - 100 Years | Johns Hopkins University | |
| Neurofibromatosis (NF) Registry Portal | NCT01885767 | Neurofibromatos... Neurofibromatos... Schwannomatosis | - | The Children's Tumor Foundation | ||
| DPCP to Treat Cutaneous Neurofibromas Associated With NF1 | NCT05438290 | Cutaneous Neuro... | DPCP | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma | NCT00589784 | CNS Cancer Meningioma Intracranial He... Hemangioblastom... Neurofibromatos... | Sunitinib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| PTC299 for Treatment of Neurofibromatosis Type 2 | NCT00911248 | Neurofibromatos... | PTC299 | 18 Years - | PTC Therapeutics | |
| Acceptance and Commitment Therapy for Adolescents and Young Adults With Neurofibromatosis and Chronic Pain | NCT01633008 | Neurofibromatos... | ACT Workshop | 12 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Clinical Hypnosis and Home Blood Pressure Monitoring in Children With Neurofibromatosis Type 1 | NCT05196854 | Hypertension Neurofibromatos... Blood Pressure | Group 1. Standa... Group 2. Hypnos... | 5 Years - 18 Years | Murdoch Childrens Research Institute | |
| Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype | NCT02298270 | Neurofibromatos... Neurofibromatos... Neurofibromatos... Schwannomatosis | The Relaxation ... | 18 Years - | Massachusetts General Hospital | |
| Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults | NCT02101736 | NF1 Neurofibromatos... Plexiform Neuro... | Cabozantinib | 3 Years - | University of Alabama at Birmingham | |
| Neurofibromatosis Type 1 Patient Registry | NCT01410006 | Neurofibromatos... | - | Washington University School of Medicine | ||
| Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas | NCT01140360 | Neurofibromatos... Neurofibromas | Gleevec | 3 Years - 65 Years | Indiana University | |
| Natural History Study of Patients With Neurofibromatosis Type 2 | NCT00598351 | Neurofibromatos... | 8 Years - 75 Years | National Institutes of Health Clinical Center (CC) | ||
| Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas | NCT01275586 | Neurofibromatos... NF1 Neurofibromas | Tasigna | 18 Years - | Indiana University | |
| Validating Pain Scales in Children and Young Adults | NCT01639950 | Sickle Cell Dis... Solid Tumor Leukemia Neurofibromatos... | 18 Years - | National Institutes of Health Clinical Center (CC) | ||
| R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas | NCT00021541 | Neurofibroma, P... Neurofibromatos... | tipifarnib placebo | 3 Years - 25 Years | National Institutes of Health Clinical Center (CC) | |
| Intervention Effectiveness on the Neurocognitive Functioning of Children and Adolescents With Neurofibromatosis Type 1 | NCT05377008 | Neurocognitive ... Mental Health I... Neurofibromatos... | OPTIMAL-SSI | 6 Years - 16 Years | Virginia Commonwealth University | |
| A Decentralized Clinical Trial to Promote Evidence-Based Care for Underserved Patients With Neurofibromatosis 1 | NCT06262113 | Neurofibromatos... | Letters about N... Letters about N... | 18 Years - | Massachusetts General Hospital | |
| How Neurofibromatosis Type 1 (NF1) Affects Schoolwork and Self-Esteem | NCT01626846 | Neurofibromatos... | 14 Years - 17 Years | John Jay High School | ||
| Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas | NCT01673009 | Neurofibromatos... | Gleevec | 3 Years - 65 Years | Indiana University | |
| Quality of Friendships in Children With Neurofibromatosis | NCT00508235 | Neurofibromatos... | Questionnaire | 8 Years - 18 Years | M.D. Anderson Cancer Center | |
| Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1 | NCT00314119 | Neurofibromatos... Neurofibroma | 20 Years - 99 Years | National Institutes of Health Clinical Center (CC) | ||
| Individual Patient Compassionate Use of Mirdametinib | NCT05028166 | Neurofibromatos... Histiocytic Neo... Other MAP-K Pat... | Mirdametinib (M... | 2 Years - | SpringWorks Therapeutics, Inc. | |
| Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults | NCT02101736 | NF1 Neurofibromatos... Plexiform Neuro... | Cabozantinib | 3 Years - | University of Alabama at Birmingham | |
| The Use of a Distress Thermometer in a Pediatric Research Setting: An Exploratory Pilot Study | NCT00824278 | Cancer HIV Infections | 7 Years - 21 Years | National Institutes of Health Clinical Center (CC) | ||
| Validating Pain Scales in Children and Young Adults | NCT01639950 | Sickle Cell Dis... Solid Tumor Leukemia Neurofibromatos... | 18 Years - | National Institutes of Health Clinical Center (CC) | ||
| Glioma Developmental and HyperActive Ras Tumor (DHART) Board | NCT05489783 | Glioma | 18 Years - | Memorial Sloan Kettering Cancer Center | ||
| Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma | NCT00589784 | CNS Cancer Meningioma Intracranial He... Hemangioblastom... Neurofibromatos... | Sunitinib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| How Neurofibromatosis Type 1 (NF1) Affects Schoolwork and Self-Esteem | NCT01626846 | Neurofibromatos... | 14 Years - 17 Years | John Jay High School | ||
| Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype | NCT02298270 | Neurofibromatos... Neurofibromatos... Neurofibromatos... Schwannomatosis | The Relaxation ... | 18 Years - | Massachusetts General Hospital | |
| Neurofibromatosis Type 1 Patient Registry | NCT01410006 | Neurofibromatos... | - | Washington University School of Medicine | ||
| Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype | NCT02298270 | Neurofibromatos... Neurofibromatos... Neurofibromatos... Schwannomatosis | The Relaxation ... | 18 Years - | Massachusetts General Hospital | |
| Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2 | NCT00004437 | Neurofibromatos... | Multichannel Au... | 12 Years - | FDA Office of Orphan Products Development | |
| PTC299 for Treatment of Neurofibromatosis Type 2 | NCT00911248 | Neurofibromatos... | PTC299 | 18 Years - | PTC Therapeutics | |
| Relationship Between Psychosocial Factors, Health Literacy, Quality of Life and Satisfaction With Medical Visits in Adults With NF | NCT02435628 | Neurofibromatos... | Questionnaires | 18 Years - | Massachusetts General Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
